Physician profile
Olaf J Rustad
NPI 1174586440
$2,378.78
in general payments reported to CMS, 2019-2025
30 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $170 · 2021: $390 · 2022: $265 · 2023: $241 · 2024: $583 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $530.70 | 2024-2025 | Daxxify |
| Organogenesis INC. | $245.91 | 2021-2024 | Affinity |
| Sun Pharmaceutical Industries INC. | $207.33 | 2019-2024 | Ilumya, Odomzo |
| Regeneron Healthcare Solutions, INC. | $164.03 | 2019-2025 | Dupixent |
| Genzyme Corporation | $141.64 | 2020-2024 | |
| Janssen Biotech, INC. | $137.26 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $101.88 | 2020-2024 | Taltz, Ebglyss |
| Ucb, INC. | $100.62 | 2019-2024 | Bimzelx |
| Incyte Corporation | $80.53 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $67.51 | 2024-2025 | Adbry |
| Galderma Laboratories, L.P. | $64.40 | 2019-2025 | Nemluvio |
| Biofrontera INC. | $56.18 | 2020-2022 | |
| Gemini Medical LLC | $43.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.11 | 2022-2023 | Sotyktu |
| Merz North America, INC. | $42.11 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.91 | 2019-2025 | |
| Pfizer INC. | $38.36 | 2021-2022 | |
| Amgen INC. | $37.47 | 2023-2024 | Otezla |
| Smith+Nephew, INC. | $31.46 | 2023-2024 | Grafix Pl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.26 | 2022-2023 | Jublia |
| Verrica Pharmaceuticals INC. | $27.91 | 2024-2025 | Ycanth |
| Stimlabs LLC | $25.31 | 2025 | Corplex P |
| Tactile Systems Technology INC | $23.29 | 2021 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $17.53 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.27 | 2019 | |
| Kerecis Limited | $14.79 | 2022 | |
| Mimedx Group, INC. | $14.19 | 2024 | |
| Celgene Corporation | $13.92 | 2019 | |
| Genentech USA, INC. | $11.89 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $9.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olaf Rustad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.